President Trump’s effort to lower drug prices haven’t hit the pharmaceutical industry’s bottom line yet, but investors are bracing for the potential impact in 2019.

Companies tend to raise treatment costs in January, and given the public pressure Trump has personally put on the industry — his involvement forced Pfizer to reverse planned price hikes earlier this year — experts say those increases are likely to be lower. Instead, investors and others say drugmakers might pursue gradual price hikes through the year in an effort to avoid public scrutiny.